Calamos Advisors LLC Sells 9,121 Shares of Gilead Sciences, Inc. $GILD

Calamos Advisors LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 225,569 shares of the biopharmaceutical company’s stock after selling 9,121 shares during the period. Calamos Advisors LLC’s holdings in Gilead Sciences were worth $27,686,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in GILD. Massachusetts Financial Services Co. MA increased its stake in Gilead Sciences by 3,763.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after acquiring an additional 4,113,999 shares during the period. First Trust Advisors LP increased its stake in Gilead Sciences by 154.3% during the 3rd quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after acquiring an additional 1,874,508 shares during the period. Invesco Ltd. increased its stake in Gilead Sciences by 12.0% during the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after acquiring an additional 1,618,453 shares during the period. Los Angeles Capital Management LLC increased its stake in Gilead Sciences by 46.7% during the 3rd quarter. Los Angeles Capital Management LLC now owns 3,845,379 shares of the biopharmaceutical company’s stock worth $426,837,000 after acquiring an additional 1,223,895 shares during the period. Finally, Danske Bank A S bought a new position in Gilead Sciences during the 3rd quarter worth $133,049,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 2.4%

NASDAQ GILD opened at $130.40 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a market cap of $161.86 billion, a price-to-earnings ratio of 19.26, a price-to-earnings-growth ratio of 1.76 and a beta of 0.39. The business’s fifty day moving average is $142.44 and its 200 day moving average is $132.02.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter last year, the business posted $1.90 EPS. Gilead Sciences’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 8.63 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were issued a dividend of $0.82 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 48.45%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the sale, the chief financial officer owned 176,191 shares of the company’s stock, valued at $24,835,883.36. This trade represents a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the insider directly owned 128,779 shares in the company, valued at approximately $18,152,687.84. This trade represents a 2.28% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 178,640 shares of company stock valued at $26,691,550 in the last 90 days. 0.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on GILD. Wolfe Research raised their target price on Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Deutsche Bank Aktiengesellschaft raised their target price on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Jefferies Financial Group began coverage on Gilead Sciences in a report on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price on the stock. Oppenheimer raised their target price on Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Finally, Wells Fargo & Company raised their target price on Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $157.35.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.